At Issue: The implications of SELECT on CVD prevention in high-risk patients with obesity

The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.
The results — a 20% reduction in CV death, MI and stroke in patients assigned semaglutide 2.4 mg (Wegovy, Novo Nordisk) compared with those assigned placebo at nearly 40 months — represent the first time a pharmacologic intervention for overweight or obesity has been shown to reduce CV complications. The findings were presented at the American

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart